Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acq - P2P | Acquired

Total Raised


About Ilex Oncology

Ilex brings novel pharmaceutical treatments for cancer patients to market, with its first drug approval in 2001. Building on the successful launch of CamPath and the initiation of clinical trials of clofarabine, Ilex is advancing an innovative pipeline of additional drug candidates.

Ilex Oncology Headquarters Location

4545 Horizon Hill Boulevard

San Antonio, Texas, 78229,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ilex Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ilex Oncology is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

  • When was Ilex Oncology founded?

    Ilex Oncology was founded in 1992.

  • Where is Ilex Oncology's headquarters?

    Ilex Oncology's headquarters is located at 4545 Horizon Hill Boulevard, San Antonio.

  • What is Ilex Oncology's latest funding round?

    Ilex Oncology's latest funding round is Acq - P2P.

  • How much did Ilex Oncology raise?

    Ilex Oncology raised a total of $26.85M.

  • Who are the investors of Ilex Oncology?

    Investors of Ilex Oncology include Genzyme, Childrens Medical Center, SMALLCAP World Fund, Franklin Templeton, Paramount Capital Asset Management and 26 more.

  • Who are Ilex Oncology's competitors?

    Competitors of Ilex Oncology include Kiadis Pharma, Charleston Laboratories, InClinica, Activate Immunotherapy, Neuraltus Pharmaceuticals and 15 more.

You May Also Like


Unibioscreen is a specialist oncology discovery & development company, with focus on 'first in class' drugs, mainly of natural origin. Unibioscreen has successfully developed 2 drug candidates from discovery to clinical development in cancer patients and has other promising pre-clinical compounds in its pipeline.

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Morria Biopharmaceuticals

Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.

InClinica Logo

InClinica, formerly IndiPharm, is a global clinical CRO that specializes in leading companies through clinical trials, and works across all phases of clinical development, with a particular strength in assisting small to mid-sized companies.

Appian International Research

Appian aims to provide consulting and operational support in pharmaceutical product development. The company grew out of the contract pharmaceutical research industry. Dr. Grier Harris, Appian's President, has worked in clinical trials since 1986 in most areas within the industry - from basic medical research to large scale international clinical trials.

Aqumen Biopharmaceuticals

The company's current portfolio of compounds and technologies in the development pipeline includes: i) A0001, Ophthalmic Dye for Retinal Surgery ii) A0003, treatments for Age-related Macular Degeneration (AMD). and iii)A0006 . Company is in negotiations to acquire rights to a Phase II program by year end 2007. The following diagram summarizes the important existing and anticipated clinical development milestones for each of the programs as they relate to their respective targeted applications:

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.